Evidence map›Paper›PMID 40788562›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

ERG expression is not predictive of outcome in patients with intermediate- and high-risk localized prostate cancer treated with combined androgen blockade and radiotherapy.

Ivan Henriquez, Barbara Malave, Gemma Benitez-Gabella, David Parada, Marta Canela, Raquel García-Pablo, Rocio Benavides, Francesc Rius, Meritxell Arenas

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ivan HenriquezDepartment of Radiation Oncology, Hospital Universitari Sant Joan, Reus, Spain. ivanhenriquezlopez@me.com.ORCID http://orcid.org/0000-0003-2771-4049
Barbara MalaveInstitut d'Investigació Sanitària Pere I Virgili (IISPV), Reus, Spain.ORCID http://orcid.org/0009-0007-4425-4060
Gemma Benitez-GabellaDepartment of Radiation Oncology, Hospital Universitari Sant Joan, Reus, Spain.
David ParadaDepartment of Pathology, Hospital Universitari Sant Joan, Reus, Spain.ORCID http://orcid.org/0000-0002-8894-2312
Marta CanelaInstitut d'Investigació Sanitària Pere I Virgili (IISPV), Reus, Spain.ORCID http://orcid.org/0000-0002-0279-206X
Raquel García-PabloInstitut d'Investigació Sanitària Pere I Virgili (IISPV), Reus, Spain.ORCID http://orcid.org/0000-0002-9188-6593
Rocio BenavidesDepartment of Radiation Oncology, Hospital Universitari Sant Joan, Reus, Spain.ORCID http://orcid.org/0009-0006-5101-3823
Francesc RiusDepartment of Pathology, Hospital Universitari Sant Joan, Reus, Spain.
Meritxell ArenasDepartment of Radiation Oncology, Hospital Universitari Sant Joan, Reus, Spain.ORCID http://orcid.org/0000-0003-0815-2570

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTMPRSS2:ERG gene fusion is a common alteration in prostate cancer and is regulated by androgen receptor signaling. We investigated whether ERG expression, assessed by immunohistochemistry (IHC), predicts clinical outcomes in patients with intermediate- or high-risk localized prostate cancer treated with combined androgen blockade (CAB) and radiotherapy (RT). MATERIAL AND

methodsWe retrospectively analyzed patients treated with CAB (GnRH agonists + antiandrogens) and normofractionated RT. ERG expression was evaluated using IHC. Overall survival (OS) was estimated with Kaplan-Meier curves. Prostate cancer-specific survival (PCSS), biochemical recurrence-free survival (bRFS), and progression-free survival (PFS) were assessed using competing risk models.

resultsA total of 86 patients were included (median follow-up 173 months). ERG expression was positive in 69%. No significant differences were observed in OS (HR 1.03; p = 0.92), PCSS (HR 0.44; p = 0.22), bRFS (HR 0.51; p = 0.19), or PFS (HR 0.56; p = 0.30) between ERG-positive and ERG-negative groups.

conclusionsERG expression assessed by IHC was not associated with clinical outcomes in this population. These results do not support its role as a predictive biomarker in patients treated with CAB and RT. Further prospective studies are warranted to confirm these findings.

Indexed as

Androgen AntagonistsProstatic NeoplasmsTranscriptional Regulator ERGAgedAged, 80 and overBiomarkers, TumorHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesAndrogen AntagonistsBiomarkers, TumorERG protein, humanTranscriptional Regulator ERGAndrogen receptor signalingImmunohistochemistryPredictive biomarkerTMPRSS2:ERG fusion

Identifiers

PMID40788562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.